Drug Safety Surveillance Based On Medicare Data Should Top List Of FDA Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Implementation of the Medicare drug benefit provides an opportunity for an active surveillance system to collect drug safety data, Drug Safety & Risk Management Advisory Committee members say. Active surveillance can act as a safety net for FDA's adverse events signaling system.
You may also be interested in...
AERS Strikes Back: FDA Anticipates Upgrade By 2008
Revamp of the Adverse Event Reporting System would include making data more accessible to public and other regulators, FDA's Seligman says.
AERS Strikes Back: FDA Anticipates Upgrade By 2008
Revamp of the Adverse Event Reporting System would include making data more accessible to public and other regulators, FDA's Seligman says.
FDA Drug Safety Committee To Discuss Use Of Post-Marketing Studies May 19
The Drug Safety & Risk Management Advisory Committee will consider the utility of various types of post-market studies in detecting and quantifying risk.